Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy

被引：7

作者：

Woell, Ewald ^{[1
]}

Eisterer, Wolfgang ^{[2
]}

Gerger, Armin ^{[3
]}

Kuehr, Thomas ^{[4
]}

Prager, Gerald W. ^{[5
]}

Rumpold, Holger ^{[6
]}

Ulrich-Pur, Herbert ^{[7
]}

Vogl, Ursula ^{[8
]}

Winder, Thomas ^{[6
]}

Weiss, Lukas ^{[9
]}

Greil, Richard ^{[9
]}

机构：

[1] St Vinzenz Hosp, Dept Internal Med, Zams, Austria

[2] Klagenfurt Hosp, Dept Internal Med & Oncol, Klagenfurt, Austria

[3] Med Univ Graz, Div Clin Oncol, Dept Internal Med, Graz, Austria

[4] Wels Grieskirchen Hosp, Dept Internal Med 4, Wels, Austria

[5] Med Univ Vienna, Dept Med 1, Vienna, Austria

[6] Acad Teaching Hosp Feldkirch, Dept Internal Med 2, Feldkirch, Austria

[7] Wilhelminenspital Stadt Wien, Dept Internal Med 1, Vienna, Austria

[8] Barmherzige Schwestern Hosp, Dept Internal Med 1, Vienna, Austria

[9] Paracelsus Med Univ Salzburg, Med Dept Haematol Med Oncol Haemostaseol Infect D, Oncol Ctr, Salzburg, Austria

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 09期

关键词：

Gastric cancer; adenocarcinoma; stomach; lower gastroesophageal junction; treatment algorithm; review; RANDOMIZED PHASE-III; OPEN-LABEL; PERIOPERATIVE CHEMOTHERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; CANCER; MULTICENTER; DOCETAXEL; PLUS; CHEMORADIOTHERAPY;

D O I：

10.21873/anticanres.13638

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite recent advances in the treatment of gastric cancer, mortality related to this disease is still substantial. Surgery and chemotherapy represent the cornerstones of patient management. Targeted treatments that include anti-angiogenic agents and the advent of immunotherapies can contribute to improved patient prognosis. Herein, we present an Austrian consensus on the systemic treatment of patients with gastric adenocarcinoma and lower gastroesophageal junction, including those with human epidermal growth factor receptor 2 (HER2)-positive disease. The consensus considers the curative setting, as well as first-line to late-line systemic treatment options in the palliative setting. For HER2-positive disease, first-line and second-line therapies are discussed, as well as HER2 testing. Potential future therapies are also listed, with a focus on anti-angiogenic treatments and checkpoint inhibition, that might provide a further step forward in the management of patients with gastric cancer.

引用

页码：4589 / 4596

页数：8

共 43 条

[31] EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients [J].

Shen, Hua ;

Zhong, Meizuo ;

Wang, Weili ;

Liao, Ping ;

Yin, Xianli ;

Rotroff, Daniel ;

Knepper, Todd C. ;

Mcleod, Howard L. ;

Zhou, Chengfang ;

Xie, Shangchen ;

Li, Wei ;

Xu, Biaobo ;

He, Yijing .

CLINICA CHIMICA ACTA, 2017, 471 :216-221

[32] Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Shitara, Kohei ;

Doi, Toshihiko ;

Dvorkin, Mikhail ;

Mansoor, Wasat ;

Arkenau, Hendrik-Tobias ;

Prokharau, Aliaksandr ;

Alsina, Maria ;

Ghidini, Michele ;

Faustino, Catia ;

Gorbunova, Vera ;

Zhavrid, Edvard ;

Nishikawa, Kazuhiro ;

Hosokawa, Ayumu ;

Yalcin, Suayib ;

Fujitani, Kazumasa ;

Beretta, Giordano D. ;

Van Cutsem, Eric ;

Winkler, Robert E. ;

Makris, Lukas ;

Ilson, David H. ;

Tabernero, Josep .

LANCET ONCOLOGY, 2018, 19 (11) :1437-1448

[33] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J].

Shitara, Kohei ;

Ozguroglu, Mustafa ;

Bang, Yung-Jue ;

Di Bartolomeo, Maria ;

Mandala, Mario ;

Ryu, Min-Hee ;

Fornaro, Lorenzo ;

Olesinski, Tomasz ;

Caglevic, Christian ;

Chung, Hyun C. ;

Muro, Kei ;

Goekkurt, Eray ;

Mansoor, Wasat ;

McDermott, Raymond S. ;

Shacham-Shmueli, Einat ;

Chen, Xinqun ;

Mayo, Carlos ;

Kang, S. Peter ;

Ohtsu, Atsushi ;

Fuchs, Charles S. .

LANCET, 2018, 392 (10142) :123-133

[34] CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer [J].

Slagter, Astrid E. ;

Jansen, Edwin P. M. ;

van Laarhoven, Hanneke W. M. ;

van Sandick, Johanna W. ;

van Grieken, Nicole C. T. ;

Sikorska, Karolina ;

Cats, Annemieke ;

Muller-Timmermans, Pietje ;

Hulshof, Maarten C. C. M. ;

Boot, Henk ;

Los, Maartje ;

Beerepoot, Laurens V. ;

Peters, Frank P. J. ;

Hospers, Geke A. P. ;

van Etten, Boudewijn ;

Hartgrink, Henk H. ;

Henegouwen, Mark I. van Berge ;

Nieuwenhuijzen, Grard A. P. ;

van Hillegersberg, Richard ;

van der Peet, Donald L. ;

Grabsch, Heike I. ;

Verheij, Marcel .

BMC CANCER, 2018, 18

[35] Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Smyth, E. C. ;

Verheij, M. ;

Allum, W. ;

Cunningham, D. ;

Cervantes, A. ;

Arnold, D. .

ANNALS OF ONCOLOGY, 2016, 27 :v38-v49

[36] Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) [J].

Thuss-Patience, Peter C. ;

Kretzschmar, Albrecht ;

Bichev, Dmitry ;

Deist, Tillman ;

Hinke, Axel ;

Breithaupt, Kirstin ;

Dogan, Yasemin ;

Gebauer, Bernhard ;

Schumacher, Guido ;

Reichardt, Peter .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (15) :2306-2314

[37] Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer [J].

van Hagen, P. ;

Hulshof, M. C. C. M. ;

van Lanschot, J. J. B. ;

Steyerberg, E. W. ;

Henegouwen, M. I. van Berge ;

Wijnhoven, B. P. L. ;

Richel, D. J. ;

Nieuwenhuijzen, G. A. P. ;

Hospers, G. A. P. ;

Bonenkamp, J. J. ;

Cuesta, M. A. ;

Blaisse, R. J. B. ;

Busch, O. R. C. ;

ten Kate, F. J. W. ;

Creemers, G. -J. ;

Punt, C. J. A. ;

Plukker, J. T. M. ;

Verheul, H. M. W. ;

Bilgen, E. J. Spillenaar ;

van Dekken, H. ;

van der Sangen, M. J. C. ;

Rozema, T. ;

Biermann, K. ;

Beukema, J. C. ;

Piet, A. H. M. ;

van Rij, C. M. ;

Reinders, J. G. ;

Tilanus, H. W. ;

van der Gaast, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) :2074-2084

[38] Modified frailty index predicts postoperative outcomes in older gastrointestinal cancer patients [J].

Vermillion, Sarah A. ;

Hsu, Fang-Chi ;

Dorrell, Robert D. ;

Shen, Perry ;

Clark, Clancy J. .

JOURNAL OF SURGICAL ONCOLOGY, 2017, 115 (08) :997-1003

[39] Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data [J].

Wagner, Anna D. ;

Grothe, Wilfried ;

Haerting, Johannes ;

Kleber, Gerhard ;

Grothey, Axel ;

Fleig, Wolfgang E. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2903-2909

[40] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [J].

Wilke, Hansjochen ;

Muro, Kei ;

Van Cutsem, Eric ;

Oh, Sang-Cheul ;

Bodoky, Gyoergy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Komatsu, Yoshito ;

Ajani, Jaffer ;

Emig, Michael ;

Carlesi, Roberto ;

Ferry, David ;

Chandrawansa, Kumari ;

Schwartz, Jonathan D. ;

Ohtsu, Atsushi .

LANCET ONCOLOGY, 2014, 15 (11) :1224-1235

← 1 2 3 4 5 →